Clinical trials sponsored by Gilead Sciences

Phase breakdown

Conditions studied

Recruiting trials led by Gilead Sciences

• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
  NCT06926920 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
  NCT06337032 · Phase: Phase 4 · Ages: 1 Month and older · Sex: All (male and female) · 15 locations
• Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
  NCT07473778 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
  NCT07527858 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Study of GS-0151 in Participants With Rheumatoid Arthritis
  NCT06902519 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 35 locations
• Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
  NCT06562907 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
  NCT07682961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 356 locations
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06029972 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 129 locations

Common questions

How many trials is Gilead Sciences recruiting for?

Gilead Sciences is the lead sponsor of 10 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.